H.C. Wainwright raised the firm’s price target on Coherus Biosciences to $12 from $11 and keeps a Buy rating on the shares post the Q1 report.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHRS:
- Coherus Biosciences Embarks on Strategic Financial Restructuring
- Coherus Biosciences announces clinical collaboration with CRI
- Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics’ ENB-003 for the Treatment of Ovarian Cancer
- CHRS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024